Provided herein is a composition of substances preferably obtained from natural sources, which is effective in preventing and/or treating iron deficiency conditions or diseases. The composition includes iron pyrophosphate, phosphatidylserine, phosphatidylcholine and starch, preferably acetylated pregelatinised starch. The formulation gives the composition gastro-resistance properties and high bioavailability of the active ingredient iron pyrophosphate. The composition is prepared in the form of a solid, semi-solid or liquid pharmaceutical dosage, preferably for oral administration.

Disclosed are bolus compositions for use in the treatment or prevention of hypocalcemia and choline deficiency in ruminants. The bolus compositions may comprise rumen-protected choline, one or more calcium salts, and water.

Disclosed are bolus compositions for use in the treatment or prevention of hypocalcemia and choline deficiency in ruminants. The bolus compositions may comprise rumen-protected choline, one or more calcium salts, and water.

The present patent application relates a process for the production of compressed tablets using specific coated particles, wherein the coating (system) comprises at least one wax and/or at least one fat. Furthermore it relates to compressed (compacted) tablets and as well as to specific coated particles.

Vitamin B1 deficiency caused when a pyridoxamine compound is administered in a large amount is prevented and/or treated. A pharmaceutical composition formed by combining at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof and at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof, is administered.

Vitamin B1 deficiency caused when a pyridoxamine compound is administered in a large amount is prevented and/or treated. A pharmaceutical composition formed by combining at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof and at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof, is administered.

A trace element solution comprises at least the following metals zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide; manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate; copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; selenium derived directly and/or indirectly from Na.sub.2SeO.sub.4 and/or Na.sub.2SeO.sub.3. The metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml. The pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable.

Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.

This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

Compositions and methods for oral and/or mucosal administration of a biologically active agent are provided according to aspects of the present disclosure which include: a plurality of particles, wherein each particle has an exterior surface, the exterior surface defining a particle interior, the exterior surface having at least one type of zwitterionic polymer and/or zwitterionic copolymer disposed thereon and/or extending therefrom; and a biologically active agent disposed on the exterior surface and/or in the particle interior, wherein the biologically active agent is or includes a protein, peptide, or dietary supplement. According to particular aspects, compositions and methods for oral and/or mucosal administration of an anti diabetes biological agent, such as insulin and/or an insulin analog.